Search

Displaying results 481 - 490 of 4188 in total
  1. Drug

    Fluoride ion F-18

    go.drugbank.com/drugs/DB09398
    ApprovedInvestigational

    No adverse reactions have been reported. … Increased deposition around joints can occur in arthritis and following trauma and increased deposition in bone has been noted around fracture sites, in osteomyelitis, fibrous dysplasia, spondylitis tuberculosa

  2. Drug

    Bimatoprost

    go.drugbank.com/drugs/DB00905
    ApprovedInvestigational

    Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution an...

  3. Drug

    Valproic acid

    go.drugbank.com/drugs/DB00313
    ApprovedInvestigational

    [L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects.

  4. Drug

    Pregabalin

    go.drugbank.com/drugs/DB00230
    ApprovedInvestigational

    [A187190] Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent

  5. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.

  6. Drug

    Eucalyptus oil

    go.drugbank.com/drugs/DB11114
    Approved

    Eucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus. It is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response. It is also shown to exhibit anti...

  7. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    It has been canceled and withdrawn from the market since August 12, 1997.[L1113]

  8. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene … [A262061] Although resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and [entrectinib], there has been no reported case of repotrectinib resistance.

  9. Drug

    Flavoxate

    go.drugbank.com/drugs/DB01148
    Approved

    A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear.

  10. Drug

    Molindone

    go.drugbank.com/drugs/DB01618
    Approved

    An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychot...